Cycle on Aug 3, 2026

I will start by listing the open threads and watches associated with this topic to see what specific questions or catalysts we should be tracking during this cycle.

I will search for the FDA's regulatory decision regarding Replimune's RP1 (vusolimogene oderparepvec) Biologics License Application (BLA) in advanced melanoma, which had a PDUFA date of August 2, 2026.

I will search to see if the FDA has announced its decision on Replimune's RP1 on or after August 2, 2026. The PDUFA date was August 2, and today is August 3, 2026. Let's run a search for "Replimune FDA approval OR CRL August 2026" or "Tudriqev approved" or similar terms.

Let's check if there has been an update today (August 3, 2026) or yesterday (August 2, 2026) about whether the FDA actually approved RP1 or issued a third CRL, or if they extended the review. Let's do a search with `sort="recent"` and `freshness="day"` or similar. Or search specifically for "Replimune press release" or check Replimune's investor relations or news page. Let's run a search for `site:ir.replimune.com`.

Let's search Google/web for any news about "Replimune" published today or in the last 24-48 hours. Let's do a search for "Replimune" with `freshness="day"` or `sort="recent"`. This is very critical because the PDUFA date was August 2, 2026 (yesterday, Sunday), and today is August 3, 2026 (Monday). Sometimes decisions are announced on Monday morning. Let's see.

Let's search for "Replimune approval" or "RP1 approved" or "Tudriqev approved" with no date limits to see if the FDA has issued its final decision yet. Let's do a search on Google. It's possible the decision is still pending or was delayed, or perhaps it was just announced today (August 3). Let's see.

Let's check if the FDA actually made a final decision on or around August 2, 2026. Let's do a search for `"vusolimogene" AND "approved" OR "complete response" OR "CRL" OR "PDUFA" OR "delayed"` to see if there is any announcement of the actual final action. Let's also check the FDA's CDER or CBER approval page or press releases. RP1 is a cellular/gene therapy product reviewed by CBER (Cellular, Tissue, and Gene Therapies Advisory Committee - CTGTAC). Let's search for "approved" on the FDA's website for August 2026. Or search Google News specifically for "Replimune" or "vusolimogene oderparepvec". Let's run a search.

Let's see if we can find any news of a decision on August 2 or August 3. Let's do a search for `"vusolimogene" OR "RP1" OR "Replimune" AND "approved"` or `"vusolimogene" OR "RP1" OR "Replimune" AND "complete response"` or `"vusolimogene" OR "RP1" OR "Replimune" AND "CRL"` on Google with `sort="recent"` and `freshness="day"`. It's possible that the FDA hasn't announced the decision yet, or it was announced very recently. Let's search.

Wait, let's fetch the page: `https://www.targetedonc.com/view/dr-vincent-ma-ctgtac-s-10-3-vote-on-rp1-nivo-is-encouraging-` to see if there is any mention of a recent FDA decision or if it is still pending. Let's do a search on Google to see if there is any other news on "Replimune" or "Tudriqev" that has been published since the PDUFA date of August 2, 2026. The PDUFA date was August 2, 2026, which was a Sunday. Let's see if there is any mention of a delay or if the FDA has not issued the decision yet. Let's do a search on Google for `"Replimune" PDUFA August 2 2026 decision` or similar. Let's search.

Ah, let's look at the LinkedIn post by Don Fink: `... Replimune's Class 1 BLA resubmission for RP1 is Sunday, August 2, 2026. Per internal FDA/CBER SOPs, when a PDUFA target action date falls on the weekend ...` Let's fetch that LinkedIn post or search for its full text if possible, or search for "Don Fink" Replimune. Wait, let's fetch the URL of the LinkedIn post or search for the text: `when a PDUFA target action date falls on the weekend` to see what happens. Usually, when a PDUFA date falls on a weekend, the FDA can issue the decision on the preceding Friday or the following Monday (which is today, August 3). Let's see if there is any other news of a decision today. Let's run a search for "Replimune" or "vusolimogene" or "Tudriqev" on Google with `sort="recent"`. Wait, we already did that and found no official announcement of an approval or CRL yet. Let's do a broader search for "PDUFA" or "FDA decisions" in August 2026 to see if there are other decisions, such as Moderna's mFlusiva (mRNA-1010) on August 5, 2026. Let's search for "Moderna mFlusiva FDA" or "mRNA-1010 approval". Let's run a search.

Excellent. So we have two major FDA events here: 1. Replimune's RP1 BLA resubmission had a PDUFA date of August 2, 2026. The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) met on July 30, 2026, and voted 10 to 3 that the efficacy results from the IGNYTE study of RP1 in combination with nivolumab are evaluable and clinically meaningful, and 10 to 3 that the benefit-risk profile is favorable in anti-PD-1-refractory advanced melanoma. This is a massive positive turnaround given that the FDA had issued highly critical briefing documents just days prior (calling the single-arm trial data "not interpretable") and had previously issued two Complete Response Letters (CRLs) in July 2025 and April 2026. Since August 2, 2026 was a Sunday, the official final FDA decision is highly anticipated and may be announced any moment (or may be slightly delayed/imminent). 2. Moderna's mFlusiva (mRNA-1010) seasonal influenza vaccine has its PDUFA date coming up on August 5, 2026 (this Wednesday). The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously (9-0) on June 18, 2026 to support its benefit-risk profile for adults 50-64 and 65+. Let's check if there are other threads/watches that are active or have recently resolved. Let's see: - Capricor's deramiocel BLA in DMD cardiomyopathy: "expected following the July 29, 2026 CTGTAC advisory committee meeting." Wait! Let's search for "Capricor deramiocel advisory committee July 2026" or "Capricor CTGTAC" to see what happened at that meeting on July 29, 2026. Let's do a search.

Let's fetch the AJMC page `https://www.ajmc.com/view/fda-advisory-panel-votes-against-approval-of-deramiocel-for-dmd` or the FierceBiotech page `https://www.fiercebiotech.com/biotech/fda-adcomm-shoots-down-capricors-duchenne-cell-therapy-after-meeting-marked-statistical` to get exact details and verbatim quotes on the Capricor deramiocel advisory committee vote. Let's do a fetch of `https://www.ajmc.com/view/fda-advisory-panel-votes-against-approval-of-deramiocel-for-dmd`.

This is extremely valuable! Let's examine the details: 1. Capricor's BLA for deramiocel (human allogeneic cardiosphere-derived cells) in DMD cardiomyopathy faced an FDA Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting on July 29, 2026. The committee voted 9 to 3 that the available data did not provide substantial evidence of effectiveness for deramiocel. The discussion was highly contentious, focusing on statistical disputes over the Statistical Analysis Plan (SAP) versions (with the FDA using an earlier prespecified SAP and Capricor asserting SAP v3.0, finalized before unblinding, should govern the interpretation of Phase 3 HOPE-3 trial data). Panelists, such as Janet Turk Wittes, characterized the efficacy findings as statistically and clinically "fragile". The PDUFA target action date is August 22, 2026 (the watch says August 31, but the actual target date is August 22, 2026). Wait, the watch `019faae7-d4d4-7d74-a6b7-85d81f6821f0` tracks the FDA's final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy, expected following the July 29, 2026 CTGTAC advisory committee meeting, with a fire date of August 31, 2026. This watch is still open and forward-looking, but we can write a note/finding detailing the advisory committee outcome since it just happened. Or we can update our findings! Let's check if there are other watches we can resolve or record events for. - Let's check: `019fb532-0016-7ab5-8085-425a945b5ccc`: "FDA final regulatory decision on Replimune's RP1 BLA in advanced melanoma" with a fire date of August 2, 2026. Wait, since the final FDA regulatory decision on Replimune's RP1 is Sunday, August 2, 2026, and today is Monday, August 3, 2026, has the decision itself been announced? Let's check if the watch has officially fired. The trigger is: "Fires when the FDA issues its final approval or CRL decision on Replimune's RP1 BLA." Since we haven't seen an official press release or FDA announcement of a final approval or CRL yet (only the advisory committee vote on July 30, which was 10-3 in favor), the final decision itself has not been officially published or is still pending. Wait, does that mean the watch is still open? Yes, we shouldn't resolve it until the final decision is issued. But wait, we can record an event for the advisory committee meeting if we want, or keep it open. Actually, the watch is specifically for the final regulatory decision (approval or CRL). So we will keep it open, but we can write a finding about the advisory committee's dramatic 10-3 endorsement of RP1, which is a major update to its regulatory path. Wait, are there other recent updates? Let's check if there are other watches that have fired: - `019faae7-d4d4-7d74-a6b7-85d81f6821f0`: "FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy" with a fire date of August 31, 2026. The PDUFA date is August 22, 2026, so this watch is also waiting for the final decision. But the advisory committee meeting just happened on July 29, 2026, and voted 9-3 against. We should write a finding about this. Let's check if there are other findings or updates we can write about. Wait! Let's check `read_notes` to see what notes currently exist on the topic, so we can see if we need to update any existing notes or create new ones. Let's do that first.

Ah, the search budget is spent. That's fine, we have excellent, highly detailed evidence for our findings. Let's see what notes we need to write or update: 1. `replimune-rp1-melanoma-fda-review`: This note already exists. Let's look at its current content or update it with the July 30, 2026 CTGTAC 10-3 vote outcome. Wait, let's look at the notes: - `replimune-rp1-melanoma-fda-review` (updated at `2026-08-02T22:46:47Z`) - `replimune-rp1-melanoma-fda-advisory-committee` (updated at `2026-08-01T22:44:38Z`) Wait, there are two notes: `replimune-rp1-melanoma-fda-review` and `replimune-rp1-melanoma-fda-advisory-committee`. Let's see if we should reuse `replimune-rp1-melanoma-fda-review` or `replimune-rp1-melanoma-fda-advisory-committee`. The guidelines say: "Name a slug for the DURABLE SUBJECT it tracks: the throughline, entity, or running debate... never the transient story-of-the-day... When this cycle advances a subject you already have a finding for, call write_note with that SAME slug to revise it in place." Let's look at the prior notes. `replimune-rp1-melanoma-fda-review` seems to be the main note for the FDA review of RP1 in advanced melanoma. Let's write the update into `replimune-rp1-melanoma-fda-review`. Wait! Let's check the other one: - `capricor-deramiocel-dmd-cardiomyopathy-fda-review` (updated at `2026-08-02T22:46:26Z`) - `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-vote` (updated at `2026-08-01T22:44:59Z`) - `capricor-deramiocel-regulatory-crisis-dmd` (updated at `2026-07-31T22:52:18Z`) Ah, there are multiple notes on Capricor. Let's update `capricor-deramiocel-dmd-cardiomyopathy-fda-review` with the latest details on the 9-3 vote against deramiocel from the July 29 CTGTAC meeting. Wait, let's check Moderna's mFlusiva flu vaccine: - `moderna-mflusiva-flu-vaccine-fda-pdufa` (updated at `2026-08-02T22:47:27Z`) Let's update `moderna-mflusiva-flu-vaccine-fda-pdufa` with the upcoming PDUFA target date of August 5, 2026, and the financial stakes and clinical trial background we retrieved. Let's read these notes first to see their current content, so we can merge/update them cleanly. Wait, since we can't use `web_search` anymore, let's see if we can use `read_notes` to see the full content of these notes. Ah, `read_notes` only returns slug, title, preview, updated_at, and source_count. It does not return the full body. But wait! We can just overwrite/update the notes with our updated comprehensive content. Let's do that. Let's carefully structure our updates. ### Note 1: `replimune-rp1-melanoma-fda-review` We will update this note to detail the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting on July 30, 2026. Key details: - Date: July 30, 2026 - Action: CTGTAC voted 10 to 3 that the efficacy results from the single-arm IGNYTE trial are evaluable and clinically meaningful, and 10 to 3 that the benefit-risk profile of RP1 (vusolimogene oderparepvec) in combination with nivolumab is favorable for adults with advanced melanoma who have progressed on prior anti-PD-1 therapy. - Context: This is a major regulatory turnaround after the FDA had issued highly critical briefing documents on July 28 calling the trial data "not interpretable" due to its single-arm design and patient retreatment protocols, and after two previous Complete Response Letters (CRLs) in July 2025 and April 2026. - Next steps: The target action date (PDUFA date) is August 2, 2026. While the FDA is not bound by the committee's vote, the strong 10-3 endorsement significantly boosts the likelihood of accelerated approval. The ongoing Phase 3 IGNYTE-3 confirmatory trial will serve as the basis for traditional approval. Let's write this note. Let's make sure it contains concrete quotes and sources. Sources to cite: - [Replimune Press Release](https://ir.replimune.com/news-releases/news-release-details/replimune-announces-favorable-outcome-fdas-cellular-tissue-and) — "Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma" - [CureToday Article](https://www.curetoday.com/view/fda-advisory-committee-backs-rp1-for-advanced-melanoma) — "FDA Advisory Committee Backs RP1 for Advanced Melanoma" - [CancerNetwork Article](https://www.cancernetwork.com/view/fda-advisory-committee-backs-rp1-nivolumab-for-advanced-melanoma) — "FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma" Let's do `write_note` for `replimune-rp1-melanoma-fda-review`. Let's construct the markdown body carefully. No YAML frontmatter. The title is the first `#` heading. Let's include 1-2 representative verbatim quotes with their links. Quote 1: From CancerNetwork: > "The FDA’s Cellular, Tissue, and Gene Therapies Adivosry Committee (CTGTAC) voted 10 to 3 that the benefit-risk profile of vusolimogene oderparepvec (RP1) in combination with nivolumab (Opdivo) is favorable for adult patients with advanced melanoma who have progressed on a prior anti–PD-1–containing regimen." Link: `https://www.cancernetwork.com/view/fda-advisory-committee-backs-rp1-nivolumab-for-advanced-melanoma` Quote 2: From Replimune Press Release: > "The committee then voted 10 to 3, on the question: “Are the efficacy results from IGNYTE evaluable and clinically meaningful?”" Link: `https://ir.replimune.com/news-releases/news-release-details/replimune-announces-favorable-outcome-fdas-cellular-tissue-and` Let's write this note.

Now let's update Note 2: `capricor-deramiocel-dmd-cardiomyopathy-fda-review`. Wait, there are three notes related to Capricor: - `capricor-deramiocel-dmd-cardiomyopathy-fda-review` - `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-vote` - `capricor-deramiocel-regulatory-crisis-dmd` Let's look at the guidelines: "Name a slug for the DURABLE SUBJECT it tracks: the throughline, entity, or running debate... never the transient story-of-the-day... When this cycle advances a subject you already have a finding for, call write_note with that SAME slug to revise it in place." Let's see. The subject is the FDA regulatory review of Capricor's deramiocel in DMD cardiomyopathy. `capricor-deramiocel-dmd-cardiomyopathy-fda-review` is the most durable and comprehensive slug for this subject. Let's write the update to `capricor-deramiocel-dmd-cardiomyopathy-fda-review`. Let's compile the details: - Date: July 29, 2026 - Action: The CTGTAC met and voted 9 to 3 (with no abstentions) that the available evidence from the Phase 3 HOPE-3 trial does not provide substantial evidence of effectiveness for deramiocel (human allogeneic cardiosphere-derived cells) in DMD cardiomyopathy. - Key controversy: Compilation of statistical analysis plan (SAP) versions. The FDA reviewers based their negative assessment on an earlier prespecified SAP. Capricor argued that SAP version 3.0, which was finalized before unblinding, was the correct basis for interpreting the Phase 3 trial results. - Panel reaction: Panelists described the efficacy findings as statistically and clinically "fragile". Janet Turk Wittes stated, "The results were very fragile. I simply didn't see enough evidence of benefit to vote yes." - Next steps: The PDUFA target action date is August 22, 2026. Following the negative panel vote, investment analysts (e.g. Piper Sandler) lowered their expectations, predicting that the FDA will issue another Complete Response Letter (CRL) rather than approve the cell therapy. This is the second review cycle for deramiocel; it received its first CRL in July 2025 due to inadequate efficacy evidence and unresolved CMC issues. Let's do `write_note` for `capricor-deramiocel-dmd-cardiomyopathy-fda-review`. Let's construct the markdown body carefully. Representative quotes: From AJMC: > "CTGTAC concluded the evidentiary package did not substantiate clinical benefit for DMD cardiomyopathy, with multiple members characterizing the efficacy findings as statistically and clinically fragile." Link: `https://www.ajmc.com/view/fda-advisory-panel-votes-against-approval-of-deramiocel-for-dmd` From AJMC (quoting Janet Turk Wittes): > "The word of the day seems to be fragile,” Janet Turk Wittes, an expert in randomized controlled trials and a member of the committee, said when explaining why she voted no. “The results were very fragile. I simply didn’t see enough evidence of benefit to vote yes." Link: `https://www.ajmc.com/view/fda-advisory-panel-votes-against-approval-of-deramiocel-for-dmd` Let's write this note.

Excellent! Now let's update Note 3: `moderna-mflusiva-flu-vaccine-fda-pdufa`. Let's see what details we have on Moderna's mFlusiva (mRNA-1010): - PDUFA target action date: August 5, 2026. - Background: This is an investigational seasonal influenza vaccine encoding surface HA glycoproteins from four WHO-recommended seasonal influenza strains (A/H1N1, A/H3N2, B/Victoria, and B/Yamagata). - Advisory Committee context: In June 2026, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously (9-0) that the benefits of mFlusiva outweigh the risks for adults aged 50-64 and 65+. - Financial stakes: The upcoming FDA decision is highly critical for Moderna, which is facing a broader 2026 loss due to pipeline spend and recently suffered a setback with its norovirus vaccine (mRNA-1403) failing an interim efficacy bar, extending its trial into a fourth season. If approved, mFlusiva would become Moderna's fifth commercial product, rebuilding its respiratory franchise ahead of the 2026–2027 flu season. - Potential risks: If the FDA does not approve, the most likely adverse scenario is a Complete Response Letter (CRL) requesting additional data for adults 65 and older. Let's do `write_note` for `moderna-mflusiva-flu-vaccine-fda-pdufa`. Representative quotes: From Conexiant: > "Moderna announced an August 5, 2026, Prescription Drug User Fee Act (PDUFA) target action date for its biologics license application for mRNA-1010, an investigational seasonal influenza vaccine. According to Moderna, the US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted unanimously that the vaccine’s benefits outweighed the risks for preventing influenza in adults aged 50 to 64 years and in adults aged 65 years or older." Link: `https://www.conexiant.com/Infectious-Disease/viewarticle?id=343ca6ba-51ad-4431-ad17-50d8169ce2f5&pub=Conexiant` From TechTimes: > "The VRBPAC voted 9–0 on June 18, 2026, to recommend mFLUSIVA for adults 50 and older — a unanimous endorsement the FDA rarely ignores." Link: `https://www.techtimes.com/articles/322405/20260731/moderna-norovirus-vaccine-fails-interim-bar-trial-extends-fourth-season.htm` Let's write this note.

Let's check if there are any other notes we should write or update. Wait, let's look at the prior notes or other watches. We have: - `019fb532-0016-7ab5-8085-425a945b5ccc`: FDA final regulatory decision on Replimune's RP1 BLA in advanced melanoma. Since we updated the note `replimune-rp1-melanoma-fda-review` with the latest CTGTAC 10-3 panel vote, but the final FDA decision itself is still pending (as August 2 was a Sunday, and as of Monday August 3, 2026, the final decision has not been officially released yet), this watch remains open. - `019faae7-d4d4-7d74-a6b7-85d81f6821f0`: FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy. Since we updated the note `capricor-deramiocel-dmd-cardiomyopathy-fda-review` with the July 29 CTGTAC 9-3 vote against recommending approval, but the final FDA decision itself is still pending (PDUFA is August 22, 2026), this watch remains open. - `019edcf0-1d32-70e1-9a3e-6825808b2370`: FDA regulatory decision on Moderna's mFlusiva mRNA flu vaccine. PDUFA is August 5, 2026. This watch remains open. Wait! Are there any other threads we can resolve or record events for? Let's review the threads. - `019fb532-0016-7ab5-8085-425a945b5ccc`: FDA final regulatory decision on Replimune's RP1 BLA in advanced melanoma. - `019faae7-d4d4-7d74-a6b7-85d81f6821f0`: FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy. - `019edcf0-1d32-70e1-9a3e-6825808b2370`: FDA regulatory decision on Moderna's mFlusiva mRNA flu vaccine. All of these are forward-looking watches tracking the actual final FDA regulatory decisions (approvals or CRLs), which have not been announced yet. So they should remain open. Wait, are there other updates or findings? No, we've updated the three most active and consequential regulatory stories in clinical medicine right now: 1. Replimune's RP1 BLA 10-3 advisory panel backing. 2. Capricor's deramiocel BLA 9-3 advisory panel rejection. 3. Moderna's mFlusiva BLA PDUFA target date of August 5, 2026, and its norovirus pipeline setback. Let's call `finish_cycle` to complete this research cycle. Since we wrote findings, we do not need to pass `no_findings_reason`. Let's invoke `finish_cycle`.

I have successfully completed the research cycle for this topic. Here is a summary of the findings and updates recorded during this cycle: ### 1. **Replimune’s RP1 Melanoma Therapy Secures Favorable 10–3 FDA Panel Backing** * **Finding Slug:** `replimune-rp1-melanoma-fda-review` (Updated) * **Status:** The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted **10 to 3** on July 30, 2026, finding that the efficacy results from the Phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) in combination with nivolumab are evaluable and clinically meaningful, and that the benefit-risk profile is favorable for advanced melanoma patients who progressed on prior anti-PD-1 therapy. * **Context:** This marks an extraordinary turnaround after the FDA released highly critical briefing documents on July 28 characterizing the data as "not interpretable" due to its single-arm design, and after issuing two prior Complete Response Letters (CRLs) in 2025 and 2026. * **Next Steps:** The Class I resubmission PDUFA target date of August 2, 2026 (a Sunday) means the final FDA decision is imminent. The randomized Phase 3 IGNYTE-3 trial remains ongoing as a confirmatory study. ### 2. **Capricor's Deramiocel Voted Down 9–3 by FDA Advisory Committee** * **Finding Slug:** `capricor-deramiocel-dmd-cardiomyopathy-fda-review` (Updated) * **Status:** On July 29, 2026, the CTGTAC voted **9 to 3** against recommending the approval of Capricor's deramiocel for Duchenne muscular dystrophy (DMD) cardiomyopathy. * **Context:** The meeting was dominated by statistical disputes regarding which version of the Statistical Analysis Plan (SAP) should govern the Phase 3 HOPE-3 trial results. Committee members sided with the FDA's cautious stance, characterizing the efficacy data as clinically and statistically "fragile." * **Next Steps:** The PDUFA target action date is August 22, 2026. Following the negative panel vote, analysts have lowered expectations, predicting a second CRL. ### 3. **Moderna’s mFlusiva Nears Historic PDUFA Target Date of August 5** * **Finding Slug:** `moderna-mflusiva-flu-vaccine-fda-pdufa` (Updated) * **Status:** Moderna is awaiting an August 5, 2026, FDA decision on its seasonal influenza vaccine **mFlusiva (mRNA-1010)**, which would mark the world's first approved mRNA flu vaccine. * **Context:** The high stakes are amplified by a recent pipeline setback on July 31, 2026, when Moderna announced that its Phase 3 norovirus vaccine candidate (mRNA-1403) failed to meet its interim efficacy bar, requiring trial extension. * **Next Steps:** A potential approval would provide Moderna with its fifth commercial product, rebuilding its respiratory franchise ahead of the 2026–2027 season. All relevant forward-looking watches remain active as we monitor the official final regulatory decisions of the FDA for these three major products.